The industry animal health divisions are now offering extended solutions for animal well-being and integrated healthcare solutions further than sole drug-development. In addition, the drug-development process itself is now tending to focus on product life-cycle management as opposed to novel drugs. To what extent is this shift observable? How does it influence the sector and what are the consequences on the stakeholders? What does it mean for collaboration opportunities?